Endo International PLC (ENDP) Shares Bought by Systematic Financial Management LP
Systematic Financial Management LP lifted its holdings in shares of Endo International PLC (NASDAQ:ENDP) (TSE:ENL) by 14.6% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 149,485 shares of the company’s stock after purchasing an additional 19,065 shares during the quarter. Systematic Financial Management LP owned about 0.07% of Endo International PLC worth $1,670,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in ENDP. Nationwide Fund Advisors grew its holdings in shares of Endo International PLC by 400.0% during the 1st quarter. Nationwide Fund Advisors now owns 343,874 shares of the company’s stock worth $3,838,000 after purchasing an additional 275,101 shares during the period. Russell Investments Group Ltd. grew its holdings in shares of Endo International PLC by 13.8% during the 1st quarter. Russell Investments Group Ltd. now owns 269,453 shares of the company’s stock worth $3,008,000 after purchasing an additional 32,760 shares during the period. Canada Pension Plan Investment Board grew its holdings in shares of Endo International PLC by 220.4% during the 1st quarter. Canada Pension Plan Investment Board now owns 292,216 shares of the company’s stock worth $3,261,000 after purchasing an additional 201,022 shares during the period. Capital Fund Management S.A. purchased a new position in shares of Endo International PLC during the 1st quarter worth $260,000. Finally, Bank of New York Mellon Corp grew its holdings in shares of Endo International PLC by 38.7% during the 1st quarter. Bank of New York Mellon Corp now owns 2,271,111 shares of the company’s stock worth $25,345,000 after purchasing an additional 633,904 shares during the period. Institutional investors and hedge funds own 90.74% of the company’s stock.
In related news, CFO Blaise Coleman purchased 6,500 shares of the company’s stock in a transaction dated Tuesday, August 15th. The shares were acquired at an average cost of $7.89 per share, for a total transaction of $51,285.00. Following the transaction, the chief financial officer now owns 13,729 shares of the company’s stock, valued at $108,321.81. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Terrance J. Coughlin purchased 20,000 shares of the company’s stock in a transaction dated Thursday, August 10th. The shares were bought at an average price of $7.70 per share, for a total transaction of $154,000.00. Following the completion of the transaction, the chief operating officer now directly owns 181,369 shares in the company, valued at approximately $1,396,541.30. The disclosure for this purchase can be found here. Insiders have acquired 36,000 shares of company stock worth $279,460 in the last 90 days. 0.50% of the stock is currently owned by insiders.
Endo International PLC (ENDP) opened at 8.60 on Friday. Endo International PLC has a 1-year low of $7.41 and a 1-year high of $23.98. The stock’s market cap is $1.92 billion. The company’s 50-day moving average price is $8.88 and its 200-day moving average price is $10.89.
Endo International PLC (NASDAQ:ENDP) (TSE:ENL) last announced its quarterly earnings data on Tuesday, August 8th. The company reported $0.93 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.74 by $0.19. Endo International PLC had a positive return on equity of 37.58% and a negative net margin of 126.93%. The firm had revenue of $875.73 million for the quarter, compared to analysts’ expectations of $832.66 million. During the same quarter in the prior year, the firm posted $0.86 earnings per share. Endo International PLC’s revenue for the quarter was down 4.9% compared to the same quarter last year. Analysts predict that Endo International PLC will post $3.52 EPS for the current year.
ENDP has been the subject of a number of research analyst reports. Oppenheimer Holdings, Inc. restated a “hold” rating on shares of Endo International PLC in a report on Sunday, July 23rd. Mizuho restated a “buy” rating and set a $14.00 target price (down from $19.00) on shares of Endo International PLC in a report on Tuesday, September 12th. William Blair restated a “market perform” rating on shares of Endo International PLC in a report on Wednesday, June 14th. Zacks Investment Research cut Endo International PLC from a “hold” rating to a “sell” rating in a report on Friday, July 28th. Finally, Canaccord Genuity set a $14.00 target price on Endo International PLC and gave the company a “hold” rating in a report on Monday, May 22nd. Three equities research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and five have issued a buy rating to the company’s stock. Endo International PLC presently has a consensus rating of “Hold” and a consensus price target of $14.33.
Endo International PLC Company Profile
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.